pbpk models and predictions of ddis (Simcyp)
90
Structured Review
Simcyp
pbpk models and predictions of ddis
Pbpk Models And Predictions Of Ddis, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pbpk+models+and+predictions+of+ddis/ddi/pm34995400-27-35-39
Average 90 stars, based on 1 article reviews
Pbpk Models And Predictions Of Ddis, supplied by Simcyp, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pbpk+models+and+predictions+of+ddis/ddi/pm34995400-27-35-39
Average 90 stars, based on 1 article reviews
pbpk models and predictions of ddis - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
In Vivo:Article Title: Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Article Snippet: Crizotinib is used for the treatment of c-ros oncogene 1–positive advanced non–small-cell lung cancer.. Triazole antifungal agents are widely used for invasive fungal infections in clinical practice.. To predict the potential influence of different triazoles (voriconazole, fluconazole, and itraconazole) on the pharmacokinetics of crizotinib by modeling and simulation the physiologically based pharmacokinetic models were established and validated in virtual cancer subjects through Simcyp software based on the essential physicochemical properties and pharmacokinetic data collected. Construct:Article Title: Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Article Snippet: Crizotinib is used for the treatment of c-ros oncogene 1–positive advanced non–small-cell lung cancer.. Triazole antifungal agents are widely used for invasive fungal infections in clinical practice.. To predict the potential influence of different triazoles (voriconazole, fluconazole, and itraconazole) on the pharmacokinetics of crizotinib by modeling and simulation the physiologically based pharmacokinetic models were established and validated in virtual cancer subjects through Simcyp software based on the essential physicochemical properties and pharmacokinetic data collected. Software:Article Title: Use of Modeling and Simulation to Predict the Influence of Triazole Antifungal Agents on the Pharmacokinetics of Crizotinib. Article Snippet: Crizotinib is used for the treatment of c-ros oncogene 1–positive advanced non–small-cell lung cancer.. Triazole antifungal agents are widely used for invasive fungal infections in clinical practice.. To predict the potential influence of different triazoles (voriconazole, fluconazole, and itraconazole) on the pharmacokinetics of crizotinib by modeling and simulation the physiologically based pharmacokinetic models were established and validated in virtual cancer subjects through Simcyp software based on the essential physicochemical properties and pharmacokinetic data collected. |